Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

Graybug Vision, a clinical-stage biopharmaceutical company specializing in retinal and optic nerve diseases, announced that its CEO, Fred Guerard, will participate in the "Goldeneye" panel at the Wedbush PacGrow Healthcare Conference on August 11, 2021, at 9:45 a.m. ET. The event will be webcast live, with a replay available for 14 days thereafter. Graybug’s innovative delivery technologies allow for sustained drug release, improving treatment for conditions like wet age-related macular degeneration and glaucoma. For further details, visit their website.

REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a panel discussion titled “Goldeneye” at the Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021 at 9:45 a.m. ET / 6:45 a.m. PT.

A live webcast of the panel will be available in the Investors and Media section of the company’s website at https://investors.graybug.vision/news-events/events-presentations. Following the live webcast, a replay will be available at the same location for 14 days.  

About Graybug

Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company’s proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybug’s lead product candidate, GB-102, a formulation of the pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib malate targeting a six-month or longer dosing regimen, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration. Graybug’s other product candidates developed using its proprietary technologies also include GB-401, an injectable sustained-release formulation of a beta-adrenergic blocker prodrug, for primary open-angle glaucoma, with a dosing regimen of once every six months or longer, and GB-103, a longer-acting version of GB-102, designed to maintain therapeutic drug levels in the retinal tissue for 12 months with a single injection. Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, Graybug is headquartered in Redwood City, California. For more information, please visit www.graybug.vision.

Investor Contact IR@graybug.vision (650) 487-2409

Media Contact media@graybug.vision (404) 384-0067

FAQ

What event will Graybug Vision participate in on August 11, 2021?

Graybug Vision will participate in the "Goldeneye" panel discussion at the Wedbush PacGrow Healthcare Conference.

Who is representing Graybug Vision at the Wedbush PacGrow Healthcare Conference?

Fred Guerard, the Chief Executive Officer of Graybug Vision, will represent the company.

How can I watch the Graybug Vision conference panel?

The panel discussion will be available via live webcast in the Investors and Media section of Graybug's website.

What are the main focuses of Graybug Vision's research?

Graybug Vision focuses on developing transformative medicines for retinal and optic nerve diseases.

What is the ticker symbol for Graybug Vision?

The ticker symbol for Graybug Vision is GRAY.